Ocera Therapeutics adds Willard Dere to board
Dr. Dere serves as the Professor of Internal Medicine; B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical and Translational Science at the University of Utah Health Sciences Center.
Prior to re-joining academia in November 2014, Dr. Dere was in the biopharmaceutical industry for 25 years.
He joined Amgen in 2003 where he held multiple roles including head of global development, international research and development, and both corporate and international chief medical officer.
He led the development program for Prolia and several other programs, and retired from Amgen in October 2014.
He began his career at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research.
While at Eli Lilly, he led the development of Evista and Forteo. Since 2014, he has been a member of the Board of Directors of Radius Health and serves on the scientific advisory board of the California Institute of Regenerative Medicine.
In addition, he joined the Board of Directors of BioMarin in July 2016.
Dr. Dere attended undergraduate and medical school at the University of California, Davis. He trained in internal medicine at the University of Utah and endocrinology/ metabolism at the University of California at San Francisco, and was on the Internal Medicine faculty at the University of Utah for 4 years during which time he was recognized annually with teaching awards.
He has published numerous articles; wrote and co-edited a primary care textbook; was awarded the 2008 transformational leadership award from his alma mater; and is a fellow in the American College of Physicians. ■
LATEST MOVES FROM California
- Banc of California names Doug Bowers as CEO
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
More inside POST